RSS feeds allow Web site content to be gathered via feed reader software. Click the subscribe link to obtain the feed URL for this page. The feed will update when new content appears on this page.

Gilead Sciences Inc.

A collection of news and information related to Gilead Sciences Inc. published by this site and its partners.

Top Gilead Sciences Inc. Articles see all

Displaying items 1-5
  • Patients pay steep price for Hepatitis C cure

    Patients pay steep price for Hepatitis C cure
    There's a new breakthrough hepatitis C drug treatment that cures — yes, cures — almost everyone who takes it. Unlike previous, far less effective treatments, patients suffer few if any side effects. The entire regimen takes only 12 weeks, much shorter than previous regimens.
  • Achillion's hepatitis C drug shows promise in trial

    (Reuters) - Achillion Pharmaceuticals Inc said all patients treated with its experimental hepatitis C drug showed no detectable levels of the virus four weeks after the therapy, sending its shares up 18 percent. The mid-stage trial tested Achillion's...

    Gilead says panel rejects Roche's claims on hepatitis C drug

    (Reuters) - Gilead Sciences Inc said an arbitration panel rejected Roche Holding AG's patent infringement claims related to Gilead's hepatitis C drug, Sovaldi. Gilead's shares rose as much as 3 percent in early trading. "While this outcome was widely...

    'Plantibodies' drugs advance as big pharma stands aside

    LOS ANGELES (Reuters) - Biotech drug production techniques based on plants, which may prove to be faster, higher yielding and cheaper than current methods using mammalian cells, haven't caught on with the biggest pharmaceutical companies. The leading...

    Healthcare: A remedy for long-term investors

    CHICAGO (Reuters) - (The opinions expressed here are those of the author, a columnist for Reuters.) For healthcare, gray is the new black. The fastest-growing segment of the global population is aged 60 and over, according to the United Nations...